Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- MU +5.8%, KMX +4.4%, MLKN +3.3%, APOG +2.0%
Other news:
- ANNX +24.7% (reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway; announces pricing of $125 million public offering of common stock)
- MGTX +22.2% (announced an asset purchase agreement with Janssen Pharmaceuticals)
- CALT +16.3% (announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function)
- IMVT +10.5% (Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease)
- IREN +7.8% (10 EH/s equity raising program complete)
- LQDA +6.0% (announces that U.S. Federal Circuit affirmed earlier decision to invalidate all claims of United Therapeutics patent No. 10,716,793)
- EXAI +4.8% (announces expansion of its current collaboration with Sanofi (SNY) to include existing exscientia programme)
- BCAB +4.0% (Chief Executive Officer / 10% owner bought 50,000 shares at $2.02 - $2.215 worth ~$107K)
- GSAT +3.5% (Director bought 750,000 shares at $1.655 - $1.70 worth ~$1.3 mln.)
- AA +2.7% (names Matt Reed as COO, effective January 1)
- MOND +2.3% (completed private placement of the Series A-3 Preferred Stock and warrants)
- BNTX +2.2% (Company and DualityBio receive FDA breakthrough therapy designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer)
- FLNC +2.1% (responds to an article reporting that it is a defendant in a counterclaim relating to its Diablo Energy Storage contract noting that it believes the counterclaim is without merit)
- QDEL +2.0% (receives 510(K) clearance for Savanna Multiplex Molecular Platform and Savanna HSV 1+2/VZV PCR assay)
- JOBY +2.0% (successfully completes series of air traffic simulations with NASA's Ames Research Center evaluating how air taxi operations can be integrated into today's airspace)
- LMND +1.9% (Co-CEOs Shai Wininger and Daniel Schreiber to return to their previously held positions as the President and CEO, respectively, effective January 1, 2024)
- BA +1.8% (secured CAAC clearance for 737 Max deliveries in China, according to Air Current)
- TSLA +1.7% (ARK Innovation ETF's are purchasing shares of Tesla (TSLA), according to Market Watch)
- IMOS +1.7% (Board approved the proposed US$137.1 million sale of the equity interests in Unimos Microelectronics (Shanghai) Co.)
- AEM +1.8% (announces financing and an earn-in agreement with FireFox Gold Corp.)
- RJF +1.5% (reports November operating data; investment banking activity remains challenging across the industry despite a healthy pipeline)
- TPH +1.4% ( announces $250 million stock repurchase program)
- BHC +1.4% (announces positive topline results from global phase 2 study evaluating amiselimod (an s1p antagonist) to treat ulcerative colitis)
- CRH +1.3% (continues share buyback program)
- UUUU +1.3% (has commenced uranium production at three of its permitted and developed uranium mines located in Arizona and Utah; expects to sell 200,000 pounds of uranium in 2024)
- E +1.1% (signs agreement for Energy Infrastructure Partners to invest in Plenitude, progressing strategy and confirming quality and value of business)
- LUV +1.0% (announces that a Tentative Agreement has been reached with the Southwest Airlines Pilots Association and will be voted on by the airline's nearly 11,000 Pilots)
Analyst comments:
- ANNX +20.1% (upgraded to Buy from Neutral at BofA Securities; tgt raised to $6)
- GKOS +3.3% (upgraded to Overweight from Neutral at JP Morgan; tgt raised to $91)
- FROG +3.0% (upgraded to Overweight from Equal-Weight at Morgan Stanley; tgt raised to $42)
- SPOT +2.6% (upgraded to Buy from Hold at Pivotal Research Group; tgt raised to $265)
- CRM +2.2% ( upgraded to Overweight from Equal-Weight at Morgan Stanley; tgt raised to $350)
- BROS +2.1% (added to Wedbush's Best Ideas List)
- OVID +1.4% ( initiated with a Buy at BTIG Research; tgt $11)
- PODD +1.1% (upgraded to Outperform from Neutral at Robert W. Baird; tgt raised to $238)
- EXR +1.0% (upgraded to Equal-Weight from Underweight at Morgan Stanley; tgt raised to $150)